Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
7 stopped studies mapped to Malignant Peripheral Nerve Sheath Tumor and descendants · 100% state a reason
Over the 7 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04530487 | Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or… | Phase 2 | terminated | Aug 28, 2020 | M.D. Anderson Cancer Center | PI Request | Other (stated, no rule matched) |
| NCT02584647 | PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath…(PLX3397) | Phase 1 / Phase 2 | terminated | Oct 22, 2015 | Gulam Manji | Poor enrollment | Enrollment / accrual |
| NCT02601209 | Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or… | Phase 1 / Phase 2 | terminated | Nov 10, 2015 | National Cancer Institute (NCI) | Interim monitoring | Other (stated, no rule matched) |
| NCT02691026 | A Study of Pembrolizumab in Patients With Malignant Peripheral Nerve Sheath Tumor… | Phase 2 | terminated | Feb 24, 2016 | Oslo University Hospital | Slow enrollment as a result of low incidence of MPNST and the COVID-19 pandemic. | COVID-19 / pandemic |
| NCT03880123 | Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma | Phase 1 | withdrawn | Mar 19, 2019 | Matthew Ingham | Study will not proceed, no participants enrolled. | Enrollment / accrual |
| NCT01418001 | Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the… | Phase 1 / Phase 2 | terminated | Aug 16, 2011 | Memorial Sloan Kettering Cancer Center | Lack of accrual | Enrollment / accrual |
| NCT00427583 | Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors | Phase 2 / Phase 3 | terminated | Jan 29, 2007 | Novartis Pharmaceuticals | stopped due to slow recruitment and no effect | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Jun 29, 2025source: clinicaltrials